[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial
Purpose The conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node dissection (PLND) represents the only reliable method, although invasive. A new amino acid PET compound, [ 18 F]-fluciclovine, was recently auth...
Saved in:
| Published in: | European journal of nuclear medicine and molecular imaging Vol. 49; no. 1; pp. 390 - 409 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.12.2021
Springer Nature B.V |
| Subjects: | |
| ISSN: | 1619-7070, 1619-7089 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Purpose
The conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node dissection (PLND) represents the only reliable method, although invasive. A new amino acid PET compound, [
18
F]-fluciclovine, was recently authorized in suspected PCa recurrence but not yet included in the standard staging work-up of primary PCa. A prospective monocentric study was designed to evaluate [
18
F]-fluciclovine PET/CT diagnostic performance for preoperative LN staging in primary high-risk PCa.
Methods
Consecutive patients (pts) with biopsy-proven PCa, standard staging (including [
11
C]choline PET/CT), eligible for PLND, were enrolled to undergo an investigational [
18
F]-fluciclovine PET/CT. Nodal uptake higher than surrounding background was reported by at least two readers (blinded to [
11
C]choline) using a visual 5-point scale (1–2 probably negative; 4–5 probably positive; 3 equivocal); SUVmax, target-to-background (aorta—A; bone marrow—BM) ratios (TBRs), were also calculated. PET results were validated with PLND. [
18
F]-fluciclovine PET/CT performance using visual score and semi-quantitative indexes was analyzed both per patient and per LN anatomical region, compared to conventional [
11
C]choline and clinical predictive factors (to note that diagnostic performance of [
18
F]-fluciclovine was explored for LNM but not examined for intrapelvic or extrapelvic M1 lesions).
Results
Overall, 94 pts underwent [
18
F]-fluciclovine PET/CT; 72/94 (77%) high-risk pts were included in the final analyses (22 pts excluded: 8 limited PLND; 3 intermediate-risk; 2 treated with radiotherapy; 4 found to be M1; 5 neoadjuvant hormonal therapy). Median LNM risk by Briganti nomogram was 19%. LNM confirmed on histology was 25% (18/72 pts). Overall, 1671 LN were retrieved; 45/1671 (3%) LNM detected. Per pt, median no. of removed LN was 22 (mean 23 ± 10; range 8–51), of LNM was 2 (mean 3 ± 2; range 1–10). Median LNM size was 5 mm (mean 5 ± 2.5; range 2–10). On patient-based analyses (n = 72), diagnostic performance for LNM resulted significant with [
18
F]-fluciclovine (AUC 0.66,
p
0.04; 50% sensitivity, 81% specificity, 47% PPV, 83% NPV, 74% accuracy), but not with [
11
C]choline (AUC 0.60,
p
0.2; 50%, 70%, 36%, 81%, and 65% respectively). Briganti nomogram (OR = 1.03,
p
= 0.04) and [
18
F]-fluciclovine visual score (≥ 4) (OR = 4.27,
p
= 0.02) resulted independent predictors of LNM at multivariable analyses. On region-based semi-quantitative analyses (n = 576), PET/CT performed better using TBR parameters (TBR-A similar to TBR-BM; TBR-A fluciclovine AUC 0.61,
p
0.35, vs choline AUC 0.57
p
0.54; TBR-BM fluciclovine AUC 0.61,
p
0.36, vs choline AUC 0.58,
p
0.52) rather than using absolute LN SUVmax (fluciclovine AUC 0.51,
p
0.91, vs choline AUC 0.51,
p
0.94). However, in all cases, diagnostic performance was not statistically significant for LNM detection, although slightly in favor of the experimental tracer [
18
F]-fluciclovine for each parameter. On the contrary, visual interpretation significantly outperformed PET semi-quantitative parameters (choline and fluciclovine: AUC 0.65 and 0.64 respectively;
p
0.03) and represents an independent predictive factor of LNM with both tracers, in particular [
18
F]-fluciclovine (OR = 8.70,
p
0.002, vs OR = 3.98,
p
= 0.03).
Conclusion
In high-risk primary PCa, [
18
F]-fluciclovine demonstrates some advantages compared with [
11
C]choline but sensitivity for metastatic LN detection is still inadequate compared to PLND. Visual (combined morphological and functional), compared to semi-quantitative assessment, is promising but relies mainly on readers’ experience rather than on unquestionable LN avidity.
Trial registration
EudraCT number: 2014–003,165-15 |
|---|---|
| AbstractList | PurposeThe conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node dissection (PLND) represents the only reliable method, although invasive. A new amino acid PET compound, [18F]-fluciclovine, was recently authorized in suspected PCa recurrence but not yet included in the standard staging work-up of primary PCa. A prospective monocentric study was designed to evaluate [18F]-fluciclovine PET/CT diagnostic performance for preoperative LN staging in primary high-risk PCa.MethodsConsecutive patients (pts) with biopsy-proven PCa, standard staging (including [11C]choline PET/CT), eligible for PLND, were enrolled to undergo an investigational [18F]-fluciclovine PET/CT. Nodal uptake higher than surrounding background was reported by at least two readers (blinded to [11C]choline) using a visual 5-point scale (1–2 probably negative; 4–5 probably positive; 3 equivocal); SUVmax, target-to-background (aorta—A; bone marrow—BM) ratios (TBRs), were also calculated. PET results were validated with PLND. [18F]-fluciclovine PET/CT performance using visual score and semi-quantitative indexes was analyzed both per patient and per LN anatomical region, compared to conventional [11C]choline and clinical predictive factors (to note that diagnostic performance of [18F]-fluciclovine was explored for LNM but not examined for intrapelvic or extrapelvic M1 lesions).ResultsOverall, 94 pts underwent [18F]-fluciclovine PET/CT; 72/94 (77%) high-risk pts were included in the final analyses (22 pts excluded: 8 limited PLND; 3 intermediate-risk; 2 treated with radiotherapy; 4 found to be M1; 5 neoadjuvant hormonal therapy). Median LNM risk by Briganti nomogram was 19%. LNM confirmed on histology was 25% (18/72 pts). Overall, 1671 LN were retrieved; 45/1671 (3%) LNM detected. Per pt, median no. of removed LN was 22 (mean 23 ± 10; range 8–51), of LNM was 2 (mean 3 ± 2; range 1–10). Median LNM size was 5 mm (mean 5 ± 2.5; range 2–10). On patient-based analyses (n = 72), diagnostic performance for LNM resulted significant with [18F]-fluciclovine (AUC 0.66, p 0.04; 50% sensitivity, 81% specificity, 47% PPV, 83% NPV, 74% accuracy), but not with [11C]choline (AUC 0.60, p 0.2; 50%, 70%, 36%, 81%, and 65% respectively). Briganti nomogram (OR = 1.03, p = 0.04) and [18F]-fluciclovine visual score (≥ 4) (OR = 4.27, p = 0.02) resulted independent predictors of LNM at multivariable analyses. On region-based semi-quantitative analyses (n = 576), PET/CT performed better using TBR parameters (TBR-A similar to TBR-BM; TBR-A fluciclovine AUC 0.61, p 0.35, vs choline AUC 0.57 p 0.54; TBR-BM fluciclovine AUC 0.61, p 0.36, vs choline AUC 0.58, p 0.52) rather than using absolute LN SUVmax (fluciclovine AUC 0.51, p 0.91, vs choline AUC 0.51, p 0.94). However, in all cases, diagnostic performance was not statistically significant for LNM detection, although slightly in favor of the experimental tracer [18F]-fluciclovine for each parameter. On the contrary, visual interpretation significantly outperformed PET semi-quantitative parameters (choline and fluciclovine: AUC 0.65 and 0.64 respectively; p 0.03) and represents an independent predictive factor of LNM with both tracers, in particular [18F]-fluciclovine (OR = 8.70, p 0.002, vs OR = 3.98, p = 0.03).ConclusionIn high-risk primary PCa, [18F]-fluciclovine demonstrates some advantages compared with [11C]choline but sensitivity for metastatic LN detection is still inadequate compared to PLND. Visual (combined morphological and functional), compared to semi-quantitative assessment, is promising but relies mainly on readers’ experience rather than on unquestionable LN avidity.Trial registrationEudraCT number: 2014–003,165-15 The conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node dissection (PLND) represents the only reliable method, although invasive. A new amino acid PET compound, [ F]-fluciclovine, was recently authorized in suspected PCa recurrence but not yet included in the standard staging work-up of primary PCa. A prospective monocentric study was designed to evaluate [ F]-fluciclovine PET/CT diagnostic performance for preoperative LN staging in primary high-risk PCa. Consecutive patients (pts) with biopsy-proven PCa, standard staging (including [ C]choline PET/CT), eligible for PLND, were enrolled to undergo an investigational [ F]-fluciclovine PET/CT. Nodal uptake higher than surrounding background was reported by at least two readers (blinded to [ C]choline) using a visual 5-point scale (1-2 probably negative; 4-5 probably positive; 3 equivocal); SUVmax, target-to-background (aorta-A; bone marrow-BM) ratios (TBRs), were also calculated. PET results were validated with PLND. [ F]-fluciclovine PET/CT performance using visual score and semi-quantitative indexes was analyzed both per patient and per LN anatomical region, compared to conventional [ C]choline and clinical predictive factors (to note that diagnostic performance of [ F]-fluciclovine was explored for LNM but not examined for intrapelvic or extrapelvic M1 lesions). Overall, 94 pts underwent [ F]-fluciclovine PET/CT; 72/94 (77%) high-risk pts were included in the final analyses (22 pts excluded: 8 limited PLND; 3 intermediate-risk; 2 treated with radiotherapy; 4 found to be M1; 5 neoadjuvant hormonal therapy). Median LNM risk by Briganti nomogram was 19%. LNM confirmed on histology was 25% (18/72 pts). Overall, 1671 LN were retrieved; 45/1671 (3%) LNM detected. Per pt, median no. of removed LN was 22 (mean 23 ± 10; range 8-51), of LNM was 2 (mean 3 ± 2; range 1-10). Median LNM size was 5 mm (mean 5 ± 2.5; range 2-10). On patient-based analyses (n = 72), diagnostic performance for LNM resulted significant with [ F]-fluciclovine (AUC 0.66, p 0.04; 50% sensitivity, 81% specificity, 47% PPV, 83% NPV, 74% accuracy), but not with [ C]choline (AUC 0.60, p 0.2; 50%, 70%, 36%, 81%, and 65% respectively). Briganti nomogram (OR = 1.03, p = 0.04) and [ F]-fluciclovine visual score (≥ 4) (OR = 4.27, p = 0.02) resulted independent predictors of LNM at multivariable analyses. On region-based semi-quantitative analyses (n = 576), PET/CT performed better using TBR parameters (TBR-A similar to TBR-BM; TBR-A fluciclovine AUC 0.61, p 0.35, vs choline AUC 0.57 p 0.54; TBR-BM fluciclovine AUC 0.61, p 0.36, vs choline AUC 0.58, p 0.52) rather than using absolute LN SUVmax (fluciclovine AUC 0.51, p 0.91, vs choline AUC 0.51, p 0.94). However, in all cases, diagnostic performance was not statistically significant for LNM detection, although slightly in favor of the experimental tracer [ F]-fluciclovine for each parameter. On the contrary, visual interpretation significantly outperformed PET semi-quantitative parameters (choline and fluciclovine: AUC 0.65 and 0.64 respectively; p 0.03) and represents an independent predictive factor of LNM with both tracers, in particular [ F]-fluciclovine (OR = 8.70, p 0.002, vs OR = 3.98, p = 0.03). In high-risk primary PCa, [ F]-fluciclovine demonstrates some advantages compared with [ C]choline but sensitivity for metastatic LN detection is still inadequate compared to PLND. Visual (combined morphological and functional), compared to semi-quantitative assessment, is promising but relies mainly on readers' experience rather than on unquestionable LN avidity. EudraCT number: 2014-003,165-15. Purpose The conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node dissection (PLND) represents the only reliable method, although invasive. A new amino acid PET compound, [ 18 F]-fluciclovine, was recently authorized in suspected PCa recurrence but not yet included in the standard staging work-up of primary PCa. A prospective monocentric study was designed to evaluate [ 18 F]-fluciclovine PET/CT diagnostic performance for preoperative LN staging in primary high-risk PCa. Methods Consecutive patients (pts) with biopsy-proven PCa, standard staging (including [ 11 C]choline PET/CT), eligible for PLND, were enrolled to undergo an investigational [ 18 F]-fluciclovine PET/CT. Nodal uptake higher than surrounding background was reported by at least two readers (blinded to [ 11 C]choline) using a visual 5-point scale (1–2 probably negative; 4–5 probably positive; 3 equivocal); SUVmax, target-to-background (aorta—A; bone marrow—BM) ratios (TBRs), were also calculated. PET results were validated with PLND. [ 18 F]-fluciclovine PET/CT performance using visual score and semi-quantitative indexes was analyzed both per patient and per LN anatomical region, compared to conventional [ 11 C]choline and clinical predictive factors (to note that diagnostic performance of [ 18 F]-fluciclovine was explored for LNM but not examined for intrapelvic or extrapelvic M1 lesions). Results Overall, 94 pts underwent [ 18 F]-fluciclovine PET/CT; 72/94 (77%) high-risk pts were included in the final analyses (22 pts excluded: 8 limited PLND; 3 intermediate-risk; 2 treated with radiotherapy; 4 found to be M1; 5 neoadjuvant hormonal therapy). Median LNM risk by Briganti nomogram was 19%. LNM confirmed on histology was 25% (18/72 pts). Overall, 1671 LN were retrieved; 45/1671 (3%) LNM detected. Per pt, median no. of removed LN was 22 (mean 23 ± 10; range 8–51), of LNM was 2 (mean 3 ± 2; range 1–10). Median LNM size was 5 mm (mean 5 ± 2.5; range 2–10). On patient-based analyses (n = 72), diagnostic performance for LNM resulted significant with [ 18 F]-fluciclovine (AUC 0.66, p 0.04; 50% sensitivity, 81% specificity, 47% PPV, 83% NPV, 74% accuracy), but not with [ 11 C]choline (AUC 0.60, p 0.2; 50%, 70%, 36%, 81%, and 65% respectively). Briganti nomogram (OR = 1.03, p = 0.04) and [ 18 F]-fluciclovine visual score (≥ 4) (OR = 4.27, p = 0.02) resulted independent predictors of LNM at multivariable analyses. On region-based semi-quantitative analyses (n = 576), PET/CT performed better using TBR parameters (TBR-A similar to TBR-BM; TBR-A fluciclovine AUC 0.61, p 0.35, vs choline AUC 0.57 p 0.54; TBR-BM fluciclovine AUC 0.61, p 0.36, vs choline AUC 0.58, p 0.52) rather than using absolute LN SUVmax (fluciclovine AUC 0.51, p 0.91, vs choline AUC 0.51, p 0.94). However, in all cases, diagnostic performance was not statistically significant for LNM detection, although slightly in favor of the experimental tracer [ 18 F]-fluciclovine for each parameter. On the contrary, visual interpretation significantly outperformed PET semi-quantitative parameters (choline and fluciclovine: AUC 0.65 and 0.64 respectively; p 0.03) and represents an independent predictive factor of LNM with both tracers, in particular [ 18 F]-fluciclovine (OR = 8.70, p 0.002, vs OR = 3.98, p = 0.03). Conclusion In high-risk primary PCa, [ 18 F]-fluciclovine demonstrates some advantages compared with [ 11 C]choline but sensitivity for metastatic LN detection is still inadequate compared to PLND. Visual (combined morphological and functional), compared to semi-quantitative assessment, is promising but relies mainly on readers’ experience rather than on unquestionable LN avidity. Trial registration EudraCT number: 2014–003,165-15 |
| Author | Porreca, Angelo Bianchi, Lorenzo Giunchi, Francesca Nanni, Cristina Zanoni, Lucia Brunocilla, Eugenio Bossert, Irene Matti, Antonella Fonti, Cristina D’Errico, Antonietta Fanti, Stefano Pultrone, Cristian Lodi, Filippo Schiavina, Riccardo Romagnoli, Daniele Fiorentino, Michelangelo |
| Author_xml | – sequence: 1 givenname: Lucia orcidid: 0000-0002-6784-8220 surname: Zanoni fullname: Zanoni, Lucia email: lucia.zanoni@aosp.bo.it organization: Nuclear Medicine, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna – sequence: 2 givenname: Lorenzo surname: Bianchi fullname: Bianchi, Lorenzo organization: Division of Urology, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Cardio-Nephro-Thoracic Sciences Doctorate, University of Bologna – sequence: 3 givenname: Cristina surname: Nanni fullname: Nanni, Cristina organization: Nuclear Medicine, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna – sequence: 4 givenname: Cristian surname: Pultrone fullname: Pultrone, Cristian organization: Division of Urology, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna – sequence: 5 givenname: Francesca surname: Giunchi fullname: Giunchi, Francesca organization: Pathology, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna – sequence: 6 givenname: Irene surname: Bossert fullname: Bossert, Irene organization: Nuclear Medicine, Istituti Clinici Scientifici Maugeri – sequence: 7 givenname: Antonella surname: Matti fullname: Matti, Antonella organization: Nuclear Medicine, IRCCS Ospedale Sacro Cuore - Don Calabria – sequence: 8 givenname: Riccardo surname: Schiavina fullname: Schiavina, Riccardo organization: Division of Urology, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Cardio-Nephro-Thoracic Sciences Doctorate, University of Bologna – sequence: 9 givenname: Michelangelo surname: Fiorentino fullname: Fiorentino, Michelangelo organization: Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna – sequence: 10 givenname: Daniele surname: Romagnoli fullname: Romagnoli, Daniele organization: Urology Unit, Abano Terme Hospital – sequence: 11 givenname: Cristina surname: Fonti fullname: Fonti, Cristina organization: Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Istituto Delle Scienze Neurologiche Di Bologna – sequence: 12 givenname: Filippo surname: Lodi fullname: Lodi, Filippo organization: Nuclear Medicine, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna – sequence: 13 givenname: Antonietta surname: D’Errico fullname: D’Errico, Antonietta organization: Pathology, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna – sequence: 14 givenname: Eugenio surname: Brunocilla fullname: Brunocilla, Eugenio organization: Division of Urology, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Cardio-Nephro-Thoracic Sciences Doctorate, University of Bologna – sequence: 15 givenname: Angelo surname: Porreca fullname: Porreca, Angelo organization: Oncological Urology, Veneto Institute of Oncology IOV - IRCCS – sequence: 16 givenname: Stefano surname: Fanti fullname: Fanti, Stefano organization: Nuclear Medicine, Istituto Di Ricovero E Cure a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria Di Bologna, DIMES, University of Bologna |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34213609$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtrGzEUhUVJaB7tH-giCLpWosc8pO6KsZtAoFk4q1CErLlylI4lV5oxZJ0_XsV2GujCqyvQdy7n3HOGjkIMgNAXRi8Zpe1VppTXilDOCK0rrkjzAZ2yhinSUqmO_r1beoLOcn6ilEku1Ud0IirOREPVKXp5YHL2i8z60Xrbx40PgO-m86vJHLuY8DpBXEMyg98ADrEzPc6DWfqwxD7gR798JMnn34XzK5Oey4zlfwBsTbCQvmHnQ9EkyGM_ZBwdNltmDXa7ckje9J_QsTN9hs_7eY7uZ9P55Jrc_vxxM_l-S2zxO5DOVZWQvFHU1VI2znUUjBBcdLxqW2ZY2y1agAV1C2tdxVwrDOfApetKVFWLc_R1t7c4-DNCHvRTHFPxlzVvWFUpWUteqIs9NS5W0Ol9NP12swLIHWBLkJzAaetLZh_DkIzvNaP6tR69q0eXevS2Ht0UKf9P-rb9oEjsRLnAYQnp3fYB1V8yUqKu |
| CitedBy_id | crossref_primary_10_3390_diagnostics14131315 crossref_primary_10_1053_j_semnuclmed_2023_06_004 crossref_primary_10_3390_cancers15194746 crossref_primary_10_1016_j_mednuc_2023_07_008 crossref_primary_10_1016_j_cpet_2022_07_005 crossref_primary_10_2147_IJGM_S351265 crossref_primary_10_1097_CCO_0000000000000932 crossref_primary_10_3390_cancers16142531 |
| Cites_doi | 10.1056/NEJMoa022749 10.1148/radiol.2017161517 10.1016/j.crad.2007.05.022 10.1016/j.eururo.2020.09.042 10.1016/j.crad.2019.06.022 10.1007/s00345-015-1669-2 10.1007/s00259-019-04505-2 10.1016/j.eururo.2008.04.030 10.1016/j.eururo.2006.08.049 10.1111/cpf.12666 10.1097/MNM.0000000000000582 10.1007/s00259-019-04614-y 10.1007/s00259-016-3329-1 10.1097/JU.0000000000001095 10.1016/j.eururo.2019.01.049 10.1016/j.adro.2019.05.008 10.1097/MNM.0000000000000040 10.1016/j.clgc.2018.05.010 10.1007/s00330-017-5213-1 10.1102/1470-7330.2009.0017 10.1007/s00259-017-3631-6 10.1002/nbm.1522 10.1007/s00259-017-3875-1 10.2214/AJR.20.24509 10.1007/s00259-012-2272-z 10.1016/j.clgc.2014.08.004 10.1016/j.eururo.2015.06.010 10.1007/s00259-017-3670-z 10.1016/j.eururo.2015.12.051 10.1097/MNM.0000000000000749 10.1111/iju.13797 10.1111/iju.14012 10.2967/jnumed.107.040097 10.1016/j.nucmedbio.2014.04.004 10.1016/j.juro.2016.09.117 10.2217/fon-2017-0446 10.1007/s00259-016-3435-0 10.1016/j.eururo.2016.01.029 10.1093/jjco/hyz072 10.1097/JU.0000000000000531 10.1007/s00259-016-3346-0 10.5301/uro.5000139 10.1016/j.clgc.2013.08.002 10.1016/0360-3016(95)02163-9 10.1016/S0090-4295(98)00518-4 10.1007/s00259-018-4066-4 10.5534/wjmh.180124 10.1016/j.eururo.2011.10.044 10.1097/MNM.0000000000001352 10.1097/RLU.0000000000000849 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 – notice: 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ P5Z P62 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS |
| DOI | 10.1007/s00259-021-05429-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection ProQuest One ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Advanced Technologies & Aerospace Database Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
| DatabaseTitleList | ProQuest Central Student MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1619-7089 |
| EndPage | 409 |
| ExternalDocumentID | 34213609 10_1007_s00259_021_05429_6 |
| Genre | Clinical Trial Journal Article |
| GrantInformation_xml | – fundername: Regione Emilia-Romagna grantid: PRUA1GR-2013-00000171 (Programma di Ricerca Regione- Università Area 1 Bando Giovani Ricercatori “Alessandro Liberati” 2013”) funderid: http://dx.doi.org/10.13039/501100009879 |
| GroupedDBID | --- -5E -5G -BR -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 203 29G 29~ 2JN 2JY 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 40D 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AACDK AAHNG AAIAL AAJBT AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDBF ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACIWK ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACUHS ACZOJ ADBBV ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AEVLU AEXYK AFBBN AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARAPS ARMRJ AXYYD AZFZN B-. B0M BA0 BBNVY BDATZ BENPR BGLVJ BGNMA BHPHI BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP DU5 EAD EAP EAS EBB EBC EBD EBLON EBO EBS EBX EHN EIHBH EIOEI EJD EMB EMK EMOBN EN4 EPL EPT ESBYG ESX EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KPH LAS LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P62 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS Q~Q R89 R9I RNI RNS ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SAP SCLPG SDH SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TH9 TSG TSK TT1 TUS U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WK8 WOW YLTOR Z45 Z7R Z7U Z7W Z7X Z7Y Z7Z Z81 Z82 Z83 Z87 Z88 Z8M Z8O Z8Q Z8R Z8S Z8T Z8U Z8V Z8W Z8Z Z91 ZMTXR ~8M AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION KOV PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS |
| ID | FETCH-LOGICAL-c342t-df44382690f5886ffd0ea3323d24771a17db7eeb0fbccf41f73a22e28fd609953 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 9 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000669193800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1619-7070 |
| IngestDate | Tue Dec 02 15:57:46 EST 2025 Thu Apr 03 07:03:56 EDT 2025 Sat Nov 29 06:11:12 EST 2025 Tue Nov 18 22:33:38 EST 2025 Fri Feb 21 02:46:45 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | High risk F]-Fluciclovine PET/CT Lymph node staging [ Prostate cancer [18F]-Fluciclovine PET/CT |
| Language | English |
| License | 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c342t-df44382690f5886ffd0ea3323d24771a17db7eeb0fbccf41f73a22e28fd609953 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| ORCID | 0000-0002-6784-8220 |
| PMID | 34213609 |
| PQID | 2614498582 |
| PQPubID | 42802 |
| PageCount | 20 |
| ParticipantIDs | proquest_journals_2614498582 pubmed_primary_34213609 crossref_citationtrail_10_1007_s00259_021_05429_6 crossref_primary_10_1007_s00259_021_05429_6 springer_journals_10_1007_s00259_021_05429_6 |
| PublicationCentury | 2000 |
| PublicationDate | 20211200 2021-12-00 20211201 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: 20211200 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | European journal of nuclear medicine and molecular imaging |
| PublicationTitleAbbrev | Eur J Nucl Med Mol Imaging |
| PublicationTitleAlternate | Eur J Nucl Med Mol Imaging |
| PublicationYear | 2021 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | SchiavinaRBianchiLBorghesiMDababnehHChessaFPultroneCVMRI displays the prostatic cancer anatomy and improves the bundles management before robot-assisted radical prostatectomyJ Endourol. Mary Ann Liebert Inc.20183231521 Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, et al. Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine ( 18 F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197. Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, et al. New clinical indications for 18F/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature [Figure presented]. Eur. Urol. Elsevier B.V.; 2016. p. 161–75. FDA approves new diagnostic imaging agent to detect recurrent prostate cancer | FDA [Internet]. [cited 2021 Feb 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-recurrent-prostate-cancer Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3–18 F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. MaurerTGschwendJERauscherISouvatzoglouMHallerBWeirichGDiagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancerJ Urol. Elsevier Inc.2016195143643 Schiavina R, Chessa F, Borghesi M, Gaudiano C, Bianchi L, Corcioni B, et al. State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. Int. J. Urol. Blackwell Publishing; 2019. p. 18–30. SchusterDMVotawJRNiehPTYuWNyeJAMasterVInitial experience with the radiotracer anti-1-amino-3-18F- fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinomaJ Nucl Med2007485663172046991:CAS:528:DC%2BD2sXhvFKmsb0%3D Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. Springer Berlin; 2017;44:1014–24 AIMN - linee-guida [Internet]. [cited 2021 Feb 7]. Available from: https://www.aimn.it/site/page/attivita/linee-guida GabrieleDColluraDOderdaMSturaIFioritoCPorpigliaFIs there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 databaseWorld J Urol Springer Verlag20163451752310.1007/s00345-015-1669-21:CAS:528:DC%2BC2MXhtlOmsrbJ HövelsAMHeesakkersRAMAdangEMJagerGJStrumSHoogeveenYLThe diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysisClin Radiol Clin Radiol20086338739510.1016/j.crad.2007.05.022 Nanni C, Zanoni L, Bach-Gansmo T, Minn H, Willoch F, Bogsrud TV, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0. Eur J Nucl Med Mol Imaging. 2020;47. McDonaldAMGalganoSJMcConathyJEYangESDobelbowerMCJacobRFeasibility of dose escalating [18F]fluciclovine positron emission tomography positive pelvic lymph nodes during moderately hypofractionated radiation therapy for high-risk prostate cancerAdv Radiat Oncol. Elsevier Inc201946495810.1016/j.adro.2019.05.008 SelnæsKMKrüger-StokkeBElschotMWillochFStørkersenØSandsmarkE18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patientsEur Radiol Springer Verlag2018283151315910.1007/s00330-017-5213-1 Hoekstra RJ, Beulens A, Vrijhof EHJEJ, Wyndaele DNJ, Roef M, Brouwer LJM, et al. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer. Nucl Med Commun. 2021;42(5):476–481. KanagawaMDoiYOkaSKobayashiRNakataNToyamaMComparison of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid (anti-[18F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in ratsNucl Med Biol. Elsevier Inc.2014415455110.1016/j.nucmedbio.2014.04.0041:CAS:528:DC%2BC2cXns1GitL8%3D UprimnyCKroissASDecristoforoCFritzJvon GuggenbergEKendlerD68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumourEur J Nucl Med Mol Imaging. Springer Berlin201744941910.1007/s00259-017-3631-61:CAS:528:DC%2BC2sXhvVSisbg%3D Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, et al. 18F-FACBC (anti1-amino-3–18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging. 2016;43. TiguertRGheilerELTefilliMVOskanianPBanerjeeMGrignonDJLymph node size does not correlate with the presence of prostate cancer metastasisUrology Urology19995336737110.1016/S0090-4295(98)00518-41:STN:280:DyaK1M7ivFygtA%3D%3D Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. Elsevier B.V.; 2020. p. 403–17. Zanoni L, Bossert I, Matti A, Schiavina R, Pultrone C, Fanti S, et al. A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer. Futur Oncol. 2018;14. JamborIKuismaAKähkönenEKemppainenJMerisaariHEskolaOProspective evaluation of 18 F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate-to high-risk prostate cancer patients (FLUCIPRO trial)Eur J Nucl Med Mol Imaging20184535536410.1007/s00259-017-3875-1 SchiavinaRScattoniVCastellucciPPicchioMCortiBBrigantiA11C-Choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomogramsEur Urol Eur Urol20085439240110.1016/j.eururo.2008.04.030 Thoeny HC, Barbieri S, Froehlich JM, Turkbey B, Choyke PL. Functional and targeted lymph node imaging in prostate cancer: current status and future challenges. Radiology. Radiological Society of North America Inc.; 2017. p. 728–43. BrigantiALarcherAAbdollahFCapitanioUGallinaASuardiNUpdated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive coresEur Urol Eur Urol20126148048710.1016/j.eururo.2011.10.044 Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier & W, Rius & M, et al. Intra-individual comparison of 68 Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(8):1400–6. CeciFCastellucciPMamedeMSchiavinaRRubelloDFuccioC11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging2013401495510.1007/s00259-012-2272-z1:CAS:528:DC%2BC3sXkvVKnsQ%3D%3D TestaCSchiavinaRLodiRSalizzoniETononCD’ErricoAAccuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsyNMR Biomed NMR Biomed2010231017102610.1002/nbm.15221:CAS:528:DC%2BC3cXhs1WrtrfE Von Eyben FE, Kairemo K. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl. Med. Commun. Nucl Med Commun; 2014. p. 221–30. TulsyanSDasCJTripathiMSethAKumarRBalCComparison of 68 Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer 68 Ga-PSMA PET and MRI in prostate cancerNucl Med Commun. Lippincott Williams and Wilkins201738109410210.1097/MNM.0000000000000749 BianchiLSchiavinaRBorghesiMCasablancaCChessaFBianchiFMPatterns of positive surgical margins after open radical prostatectomy and their association with clinical recurrenceMinerva Urol e Nefrol. Edizioni Minerva Medica20207246473 AlemozaffarMAkintayoAAAbiodun-OjoOAPatilDSaeedFHuangY18F]Fluciclovine positron emission tomography/computerized tomography for preoperative staging in patients with intermediate to high risk primary prostate cancerJ Urol NLM (Medline)202020473474010.1097/JU.0000000000001095 Galgano SJ, Mcdonald A, Rais-Bahrami S, Porter KK, Choudhary G, Burgan C, et al. Utility of 18F-fluciclovine PET/MRI for staging newly diagnosed high-risk prostate cancer and evaluating response to initial androgen deprivation therapy: a prospective single-arm pilot study.AJR Am J Roentgenol. 2020 Oct 14. Farolfi A Ceci F Castellucci P Graziani T Siepe G Lambertini A et al 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml Efficacy and impact on treatment strategy Eur J Nucl Med Mol Imaging Springer Berlin Heidelberg 2019 4611 9 SchiavinaRBianchiLMineo BianchiFBorghesiMPultroneCVDababnehHPreoperative staging with 11C-choline PET/CT is adequately accurate in patients with very high-risk prostate cancerClin Genitourin Cancer Elsevier Inc201816305312.e110.1016/j.clgc.2018.05.010 WeckermannDDornRHollGWagnerTHarzmannRLimitations of radioguided surgery in high-risk prostate cancerEur Urol Eur Urol2007511549155810.1016/j.eururo.2006.08.049 SchiavinaRCapizziEBorghesiMVagnoniVRomagnoliDRoccaGCNodal occult metastases in intermediate- and high-risk prostate cancer patients detected using serial section, immunohistochemistry, and real-time reverse transcriptase polymerase chain reaction: Prospective evaluation with matched-pair analysisClin Genitourin Cancer. Elsevier Inc.201513e55e6410.1016/j.clgc.2014.08.004 European Pharmacopoeia (Ph. Eur.) 10th Edition | EDQM - European Directorate for the Quality of Medicines [Internet]. [cited 2021 Feb 7]. Available from: https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-10th-e R Schiavina (5429_CR4) 2018; 32 DM Schuster (5429_CR67) 2014; 55 F Ceci (5429_CR13) 2020; 47 S Ganeshalingam (5429_CR6) 2009; 9 L Budäus (5429_CR66) 2016; 69 5429_CR5 L Bianchi (5429_CR14) 2019; 26 M Kanagawa (5429_CR34) 2014; 41 5429_CR1 5429_CR2 R Schiavina (5429_CR55) 2015; 13 5429_CR28 5429_CR29 5429_CR26 5429_CR27 D Gabriele (5429_CR47) 2016; 34 5429_CR8 5429_CR24 I Jambor (5429_CR40) 2018; 45 5429_CR68 DM Schuster (5429_CR17) 2007; 48 DM Schuster (5429_CR21) 2013; 3 5429_CR25 5429_CR22 5429_CR23 5429_CR20 A Herlemann (5429_CR58) 2016; 70 5429_CR63 5429_CR61 KM Selnæs (5429_CR39) 2018; 28 MG Harisinghani (5429_CR45) 2003; 348 L Bianchi (5429_CR32) 2020; 72 C Testa (5429_CR3) 2010; 23 L Spevack (5429_CR50) 1996; 34 R Schiavina (5429_CR52) 2008; 54 AM McDonald (5429_CR54) 2019; 4 S Hijazi (5429_CR59) 2015; 75 5429_CR18 MP Miller (5429_CR53) 2017; 58 5429_CR15 R Schiavina (5429_CR9) 2018; 16 S Tulsyan (5429_CR64) 2017; 38 5429_CR12 5429_CR10 F Ceci (5429_CR7) 2013; 40 R Tiguert (5429_CR49) 1999; 53 5429_CR51 LWM van Kalmthout (5429_CR62) 2020; 203 SJ Kim (5429_CR36) 2019; 74 T Pyka (5429_CR60) 2016; 43 M Alemozaffar (5429_CR38) 2020; 204 H Suzuki (5429_CR35) 2019; 49 C Uprimny (5429_CR65) 2017; 44 5429_CR44 5429_CR42 5429_CR43 5429_CR41 D Weckermann (5429_CR11) 2007; 51 A Briganti (5429_CR16) 2012; 61 P Borrelli (5429_CR56) 2021; 41 AM Hövels (5429_CR46) 2008; 63 T Maurer (5429_CR57) 2016; 195 RC Flanigan (5429_CR48) 1996; 48 5429_CR37 JA Nye (5429_CR19) 2007; 48 5429_CR33 5429_CR31 5429_CR30 |
| References_xml | – reference: Farolfi A Ceci F Castellucci P Graziani T Siepe G Lambertini A et al 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml Efficacy and impact on treatment strategy Eur J Nucl Med Mol Imaging Springer Berlin Heidelberg 2019 4611 9 – reference: Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier & W, Rius & M, et al. Intra-individual comparison of 68 Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(8):1400–6. – reference: SchiavinaRScattoniVCastellucciPPicchioMCortiBBrigantiA11C-Choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomogramsEur Urol Eur Urol20085439240110.1016/j.eururo.2008.04.030 – reference: TiguertRGheilerELTefilliMVOskanianPBanerjeeMGrignonDJLymph node size does not correlate with the presence of prostate cancer metastasisUrology Urology19995336737110.1016/S0090-4295(98)00518-41:STN:280:DyaK1M7ivFygtA%3D%3D – reference: Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. Springer Berlin; 2017;44:1014–24 – reference: SchusterDMVotawJRNiehPTYuWNyeJAMasterVInitial experience with the radiotracer anti-1-amino-3-18F- fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinomaJ Nucl Med2007485663172046991:CAS:528:DC%2BD2sXhvFKmsb0%3D – reference: BianchiLSchiavinaRBorghesiMCasablancaCChessaFBianchiFMPatterns of positive surgical margins after open radical prostatectomy and their association with clinical recurrenceMinerva Urol e Nefrol. Edizioni Minerva Medica20207246473 – reference: Thoeny HC, Barbieri S, Froehlich JM, Turkbey B, Choyke PL. Functional and targeted lymph node imaging in prostate cancer: current status and future challenges. Radiology. Radiological Society of North America Inc.; 2017. p. 728–43. – reference: Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, et al. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. Urologia. Urologia; 2017. p. 9–19. – reference: HerlemannAWenterVKretschmerAThierfelderKMBartensteinPFaberC68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancerEur Urol. Elsevier B.V.201670553710.1016/j.eururo.2015.12.0511:CAS:528:DC%2BC28XntVajtg%3D%3D – reference: HijaziSMellerBLeitsmannCStraussAMellerJRitterCOPelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomographyProstate. John Wiley and Sons Inc.2015751934401:CAS:528:DC%2BC2MXhslSrtbzM – reference: AIMN - linee-guida [Internet]. [cited 2021 Feb 7]. Available from: https://www.aimn.it/site/page/attivita/linee-guida – reference: van KalmthoutLWMvan MelickHHELavalayeJMeijerRPKooistraAde KlerkJMHProspective validation of gallium-68 prostate specific membrane antigen-positron emission tomography/computerized tomography for primary staging of prostate cancerJ Urol NLM (Medline)202020353754510.1097/JU.0000000000000531 – reference: Galgano SJ, Mcdonald A, Rais-Bahrami S, Porter KK, Choudhary G, Burgan C, et al. Utility of 18F-fluciclovine PET/MRI for staging newly diagnosed high-risk prostate cancer and evaluating response to initial androgen deprivation therapy: a prospective single-arm pilot study.AJR Am J Roentgenol. 2020 Oct 14. – reference: BrigantiALarcherAAbdollahFCapitanioUGallinaASuardiNUpdated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive coresEur Urol Eur Urol20126148048710.1016/j.eururo.2011.10.044 – reference: HarisinghaniMGBarentszJHahnPFDesernoWMTabatabaeiSvan de KaaCHNoninvasive detection of clinically occult lymph-node metastases in prostate cancerN Engl J Med. New England Journal of Medicine (NEJM/MMS)20033482491910.1056/NEJMoa022749 – reference: BianchiLSchiavinaRBorghesiMCeciFAngioliniAChessaFHow does 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?Int J Urol Blackwell Publishing20192680481110.1111/iju.14012 – reference: FlaniganRCMcKayTCOlsonMShankeyTVPyleJWatersWBLimited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. UrologyElsevier Inc.199648428321:STN:280:DyaK28zpslKjsQ%3D%3D – reference: MillerMPKostakogluLPrymaDYuJQChauAPerlmanEReader training for the restaging of biochemically recurrent prostate cancer using 18F-fluciclovine PET/CTJ Nucl Med. Society of Nuclear Medicine Inc.20175815966021:CAS:528:DC%2BC1cXitVCqu7jI – reference: GaneshalingamSKohD-MARTICLE Nodal stagingCancer Imaging2009910411110.1102/1470-7330.2009.0017 – reference: TulsyanSDasCJTripathiMSethAKumarRBalCComparison of 68 Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer 68 Ga-PSMA PET and MRI in prostate cancerNucl Med Commun. Lippincott Williams and Wilkins201738109410210.1097/MNM.0000000000000749 – reference: MaurerTGschwendJERauscherISouvatzoglouMHallerBWeirichGDiagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancerJ Urol. Elsevier Inc.2016195143643 – reference: SuzukiHJinnouchiSKajiYKishidaTKinoshitaHYamaguchiSDiagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trialJpn J Clin Oncol. Oxford University Press2019498031110.1093/jjco/hyz072 – reference: SchusterDMNanniCFantiSOkaSOkudairaHInoueYAnti-1-amino-3–18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate diseaseJ Nucl Med. Society of Nuclear Medicine Inc.2014551986921:CAS:528:DC%2BC2MXislegtA%3D%3D – reference: SchiavinaRBianchiLMineo BianchiFBorghesiMPultroneCVDababnehHPreoperative staging with 11C-choline PET/CT is adequately accurate in patients with very high-risk prostate cancerClin Genitourin Cancer Elsevier Inc201816305312.e110.1016/j.clgc.2018.05.010 – reference: TestaCSchiavinaRLodiRSalizzoniETononCD’ErricoAAccuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsyNMR Biomed NMR Biomed2010231017102610.1002/nbm.15221:CAS:528:DC%2BC3cXhs1WrtrfE – reference: Zanoni L, Bossert I, Matti A, Schiavina R, Pultrone C, Fanti S, et al. A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer. Futur Oncol. 2018;14. – reference: JamborIKuismaAKähkönenEKemppainenJMerisaariHEskolaOProspective evaluation of 18 F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate-to high-risk prostate cancer patients (FLUCIPRO trial)Eur J Nucl Med Mol Imaging20184535536410.1007/s00259-017-3875-1 – reference: SchusterDMTaleghaniPANiehPTMasterVAAmzatRSavir-BaruchBCharacterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptakeAm J Nucl Med Mol Imaging e-Century Publishing Corporation2013385961:CAS:528:DC%2BC3sXit1Cgur8%3D – reference: McDonaldAMGalganoSJMcConathyJEYangESDobelbowerMCJacobRFeasibility of dose escalating [18F]fluciclovine positron emission tomography positive pelvic lymph nodes during moderately hypofractionated radiation therapy for high-risk prostate cancerAdv Radiat Oncol. Elsevier Inc201946495810.1016/j.adro.2019.05.008 – reference: Wu H, Xu T, Wang X, Yu YB, Fan ZY, Li DX, et al. Diagnostic performance of 68gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysis. World J. Mens. Health. Korean Society for Sexual Medicine and Andrology; 2020. p. 208–19. – reference: Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. Elsevier B.V.; 2020. p. 403–17. – reference: FDA approves new diagnostic imaging agent to detect recurrent prostate cancer | FDA [Internet]. [cited 2021 Feb 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-recurrent-prostate-cancer – reference: KanagawaMDoiYOkaSKobayashiRNakataNToyamaMComparison of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid (anti-[18F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in ratsNucl Med Biol. Elsevier Inc.2014415455110.1016/j.nucmedbio.2014.04.0041:CAS:528:DC%2BC2cXns1GitL8%3D – reference: PykaTOkamotoSDahlbenderMTauberRRetzMHeckMComparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancerEur J Nucl Med Mol Imaging. Springer Berlin20164321142110.1007/s00259-016-3435-01:CAS:528:DC%2BC28XpvV2ntL0%3D – reference: Hoekstra RJ, Beulens A, Vrijhof EHJEJ, Wyndaele DNJ, Roef M, Brouwer LJM, et al. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer. Nucl Med Commun. 2021;42(5):476–481. – reference: Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, et al. 18F-FACBC (anti1-amino-3–18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging. 2016;43. – reference: SpevackLKillionLTWestJCRookerGMBrewerEACuddyPGPredicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical modelsInt J Radiat Oncol Biol Phys. Elsevier Inc.199634543710.1016/0360-3016(95)02163-91:STN:280:DyaK287os1GntA%3D%3D – reference: EAU Guidelines: Prostate cancer | Uroweb [Internet]. [cited 2020 Nov 30]. Available from: https://uroweb.org/guideline/prostate-cancer/ – reference: WeckermannDDornRHollGWagnerTHarzmannRLimitations of radioguided surgery in high-risk prostate cancerEur Urol Eur Urol2007511549155810.1016/j.eururo.2006.08.049 – reference: Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, et al. New clinical indications for 18F/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature [Figure presented]. Eur. Urol. Elsevier B.V.; 2016. p. 161–75. – reference: Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: A prospective study in 28 patients. Clin Genitourin Cancer. 2014;12. – reference: GabrieleDColluraDOderdaMSturaIFioritoCPorpigliaFIs there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 databaseWorld J Urol Springer Verlag20163451752310.1007/s00345-015-1669-21:CAS:528:DC%2BC2MXhtlOmsrbJ – reference: Von Eyben FE, Kairemo K. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl. Med. Commun. Nucl Med Commun; 2014. p. 221–30. – reference: UprimnyCKroissASDecristoforoCFritzJvon GuggenbergEKendlerD68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumourEur J Nucl Med Mol Imaging. Springer Berlin201744941910.1007/s00259-017-3631-61:CAS:528:DC%2BC2sXhvVSisbg%3D – reference: Mottet N, Bellmunt J, Briers E, Bergh RCN van den, Bolla M, Casteren NJ van, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–262. – reference: BorrelliPLarssonMUlénJEnqvistOTrägårdhEPoulsenMHArtificial intelligence-based detection of lymph node metastases by PET/CT predicts prostate cancer-specific survivalClin Physiol Funct Imaging. Blackwell Publishing Ltd20214162710.1111/cpf.126661:CAS:528:DC%2BB3MXht1Oisbc%3D – reference: SchiavinaRCapizziEBorghesiMVagnoniVRomagnoliDRoccaGCNodal occult metastases in intermediate- and high-risk prostate cancer patients detected using serial section, immunohistochemistry, and real-time reverse transcriptase polymerase chain reaction: Prospective evaluation with matched-pair analysisClin Genitourin Cancer. Elsevier Inc.201513e55e6410.1016/j.clgc.2014.08.004 – reference: Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu W, et al. A preliminary study of anti-1-amino-3–18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med. 2007;48. – reference: KimSJLeeSWThe role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysisClin Radiol. W.B. Saunders Ltd2019748869210.1016/j.crad.2019.06.022 – reference: AlemozaffarMAkintayoAAAbiodun-OjoOAPatilDSaeedFHuangY18F]Fluciclovine positron emission tomography/computerized tomography for preoperative staging in patients with intermediate to high risk primary prostate cancerJ Urol NLM (Medline)202020473474010.1097/JU.0000000000001095 – reference: Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, et al. 18F-Fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-Choline PET/CT. Clin Nucl Med. 2015;40. – reference: NyeJASchusterDMYuWCampVMGoodmanMMVotawJRBiodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humansJ Nucl Med J Nucl Med2007481017102010.2967/jnumed.107.0400971:CAS:528:DC%2BD2sXhtVertL7M – reference: Schiavina R, Bertaccini A, Franceschelli A, Manferrari F, Vagnoni V, Borghesi M, et al. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients. Anticancer Res. 2010;30(6):2297–302. – reference: Sörensen J, Owenius R, Lax M, Johansson S. Regional distribution and kinetics of [ 18 F]fluciclovine (anti-[ 18 F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. – reference: Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, et al. Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine ( 18 F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197. – reference: BudäusLLeyh-BannurahSRSalomonGMichlUHeinzerHHulandHInitial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomyEur Urol. Elsevier B.V.201669393610.1016/j.eururo.2015.06.010 – reference: Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3–18 F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. – reference: SchiavinaRBianchiLBorghesiMDababnehHChessaFPultroneCVMRI displays the prostatic cancer anatomy and improves the bundles management before robot-assisted radical prostatectomyJ Endourol. Mary Ann Liebert Inc.20183231521 – reference: Schiavina R, Chessa F, Borghesi M, Gaudiano C, Bianchi L, Corcioni B, et al. State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. Int. J. Urol. Blackwell Publishing; 2019. p. 18–30. – reference: CeciFCastellucciPMamedeMSchiavinaRRubelloDFuccioC11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging2013401495510.1007/s00259-012-2272-z1:CAS:528:DC%2BC3sXkvVKnsQ%3D%3D – reference: Axumin | European Medicines Agency [Internet]. [cited 2021 Feb 7]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/axumin – reference: CeciFBianchiLBorghesiMPolverariGFarolfiABrigantiAPrediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancerEur J Nucl Med Mol Imaging. Springer2020471364610.1007/s00259-019-04505-21:CAS:528:DC%2BC1MXhslKnt7vE – reference: HövelsAMHeesakkersRAMAdangEMJagerGJStrumSHoogeveenYLThe diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysisClin Radiol Clin Radiol20086338739510.1016/j.crad.2007.05.022 – reference: European Pharmacopoeia (Ph. Eur.) 10th Edition | EDQM - European Directorate for the Quality of Medicines [Internet]. [cited 2021 Feb 7]. Available from: https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-10th-edition – reference: SelnæsKMKrüger-StokkeBElschotMWillochFStørkersenØSandsmarkE18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patientsEur Radiol Springer Verlag2018283151315910.1007/s00330-017-5213-1 – reference: Evangelista L, Zattoni F, Karnes RJ, Novara G, Lowe V. Radiolabeled choline PET/CT before salvage lymphadenectomy dissection: a systematic review and meta-analysis. Nucl. Med. Commun. Lippincott Williams and Wilkins; 2016. p. 1223–31. – reference: Nanni C, Zanoni L, Bach-Gansmo T, Minn H, Willoch F, Bogsrud TV, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0. Eur J Nucl Med Mol Imaging. 2020;47. – volume: 3 start-page: 85 year: 2013 ident: 5429_CR21 publication-title: Am J Nucl Med Mol Imaging e-Century Publishing Corporation – volume: 348 start-page: 2491 year: 2003 ident: 5429_CR45 publication-title: N Engl J Med. New England Journal of Medicine (NEJM/MMS) doi: 10.1056/NEJMoa022749 – ident: 5429_CR10 doi: 10.1148/radiol.2017161517 – volume: 63 start-page: 387 year: 2008 ident: 5429_CR46 publication-title: Clin Radiol Clin Radiol doi: 10.1016/j.crad.2007.05.022 – volume: 75 start-page: 1934 year: 2015 ident: 5429_CR59 publication-title: Prostate. John Wiley and Sons Inc. – ident: 5429_CR27 – ident: 5429_CR2 doi: 10.1016/j.eururo.2020.09.042 – volume: 74 start-page: 886 year: 2019 ident: 5429_CR36 publication-title: Clin Radiol. W.B. Saunders Ltd doi: 10.1016/j.crad.2019.06.022 – volume: 34 start-page: 517 year: 2016 ident: 5429_CR47 publication-title: World J Urol Springer Verlag doi: 10.1007/s00345-015-1669-2 – volume: 32 start-page: 315 year: 2018 ident: 5429_CR4 publication-title: J Endourol. Mary Ann Liebert Inc. – volume: 58 start-page: 1596 year: 2017 ident: 5429_CR53 publication-title: J Nucl Med. Society of Nuclear Medicine Inc. – volume: 47 start-page: 136 year: 2020 ident: 5429_CR13 publication-title: Eur J Nucl Med Mol Imaging. Springer doi: 10.1007/s00259-019-04505-2 – volume: 54 start-page: 392 year: 2008 ident: 5429_CR52 publication-title: Eur Urol Eur Urol doi: 10.1016/j.eururo.2008.04.030 – volume: 55 start-page: 1986 year: 2014 ident: 5429_CR67 publication-title: J Nucl Med. Society of Nuclear Medicine Inc. – volume: 195 start-page: 1436 year: 2016 ident: 5429_CR57 publication-title: J Urol. Elsevier Inc. – volume: 51 start-page: 1549 year: 2007 ident: 5429_CR11 publication-title: Eur Urol Eur Urol doi: 10.1016/j.eururo.2006.08.049 – volume: 41 start-page: 62 year: 2021 ident: 5429_CR56 publication-title: Clin Physiol Funct Imaging. Blackwell Publishing Ltd doi: 10.1111/cpf.12666 – volume: 72 start-page: 464 year: 2020 ident: 5429_CR32 publication-title: Minerva Urol e Nefrol. Edizioni Minerva Medica – ident: 5429_CR43 doi: 10.1097/MNM.0000000000000582 – ident: 5429_CR51 doi: 10.1007/s00259-019-04614-y – ident: 5429_CR22 doi: 10.1007/s00259-016-3329-1 – volume: 204 start-page: 734 year: 2020 ident: 5429_CR38 publication-title: J Urol NLM (Medline) doi: 10.1097/JU.0000000000001095 – ident: 5429_CR61 doi: 10.1016/j.eururo.2019.01.049 – volume: 4 start-page: 649 year: 2019 ident: 5429_CR54 publication-title: Adv Radiat Oncol. Elsevier Inc doi: 10.1016/j.adro.2019.05.008 – ident: 5429_CR42 doi: 10.1097/MNM.0000000000000040 – ident: 5429_CR20 – ident: 5429_CR18 – ident: 5429_CR28 – ident: 5429_CR30 – volume: 16 start-page: 305 year: 2018 ident: 5429_CR9 publication-title: Clin Genitourin Cancer Elsevier Inc doi: 10.1016/j.clgc.2018.05.010 – volume: 28 start-page: 3151 year: 2018 ident: 5429_CR39 publication-title: Eur Radiol Springer Verlag doi: 10.1007/s00330-017-5213-1 – volume: 9 start-page: 104 year: 2009 ident: 5429_CR6 publication-title: Cancer Imaging doi: 10.1102/1470-7330.2009.0017 – volume: 44 start-page: 941 year: 2017 ident: 5429_CR65 publication-title: Eur J Nucl Med Mol Imaging. Springer Berlin doi: 10.1007/s00259-017-3631-6 – volume: 23 start-page: 1017 year: 2010 ident: 5429_CR3 publication-title: NMR Biomed NMR Biomed doi: 10.1002/nbm.1522 – volume: 45 start-page: 355 year: 2018 ident: 5429_CR40 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-017-3875-1 – ident: 5429_CR41 doi: 10.2214/AJR.20.24509 – volume: 40 start-page: 149 year: 2013 ident: 5429_CR7 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-012-2272-z – volume: 13 start-page: e55 year: 2015 ident: 5429_CR55 publication-title: Clin Genitourin Cancer. Elsevier Inc. doi: 10.1016/j.clgc.2014.08.004 – volume: 69 start-page: 393 year: 2016 ident: 5429_CR66 publication-title: Eur Urol. Elsevier B.V. doi: 10.1016/j.eururo.2015.06.010 – ident: 5429_CR15 doi: 10.1007/s00259-017-3670-z – volume: 70 start-page: 553 year: 2016 ident: 5429_CR58 publication-title: Eur Urol. Elsevier B.V. doi: 10.1016/j.eururo.2015.12.051 – volume: 38 start-page: 1094 year: 2017 ident: 5429_CR64 publication-title: Nucl Med Commun. Lippincott Williams and Wilkins doi: 10.1097/MNM.0000000000000749 – ident: 5429_CR8 doi: 10.1111/iju.13797 – ident: 5429_CR29 – volume: 48 start-page: 428 year: 1996 ident: 5429_CR48 publication-title: Elsevier Inc. – volume: 26 start-page: 804 year: 2019 ident: 5429_CR14 publication-title: Int J Urol Blackwell Publishing doi: 10.1111/iju.14012 – volume: 48 start-page: 1017 year: 2007 ident: 5429_CR19 publication-title: J Nucl Med J Nucl Med doi: 10.2967/jnumed.107.040097 – volume: 41 start-page: 545 year: 2014 ident: 5429_CR34 publication-title: Nucl Med Biol. Elsevier Inc. doi: 10.1016/j.nucmedbio.2014.04.004 – ident: 5429_CR26 doi: 10.1016/j.juro.2016.09.117 – ident: 5429_CR31 – ident: 5429_CR25 doi: 10.2217/fon-2017-0446 – volume: 43 start-page: 2114 year: 2016 ident: 5429_CR60 publication-title: Eur J Nucl Med Mol Imaging. Springer Berlin doi: 10.1007/s00259-016-3435-0 – ident: 5429_CR44 doi: 10.1016/j.eururo.2016.01.029 – volume: 49 start-page: 803 year: 2019 ident: 5429_CR35 publication-title: Jpn J Clin Oncol. Oxford University Press doi: 10.1093/jjco/hyz072 – volume: 48 start-page: 56 year: 2007 ident: 5429_CR17 publication-title: J Nucl Med – volume: 203 start-page: 537 year: 2020 ident: 5429_CR62 publication-title: J Urol NLM (Medline) doi: 10.1097/JU.0000000000000531 – ident: 5429_CR1 – ident: 5429_CR68 doi: 10.1007/s00259-016-3346-0 – ident: 5429_CR33 doi: 10.5301/uro.5000139 – ident: 5429_CR5 – ident: 5429_CR23 doi: 10.1016/j.clgc.2013.08.002 – volume: 34 start-page: 543 year: 1996 ident: 5429_CR50 publication-title: Int J Radiat Oncol Biol Phys. Elsevier Inc. doi: 10.1016/0360-3016(95)02163-9 – volume: 53 start-page: 367 year: 1999 ident: 5429_CR49 publication-title: Urology Urology doi: 10.1016/S0090-4295(98)00518-4 – ident: 5429_CR12 doi: 10.1007/s00259-018-4066-4 – ident: 5429_CR63 doi: 10.5534/wjmh.180124 – volume: 61 start-page: 480 year: 2012 ident: 5429_CR16 publication-title: Eur Urol Eur Urol doi: 10.1016/j.eururo.2011.10.044 – ident: 5429_CR37 doi: 10.1097/MNM.0000000000001352 – ident: 5429_CR24 doi: 10.1097/RLU.0000000000000849 |
| SSID | ssj0018289 |
| Score | 2.3990133 |
| Snippet | Purpose
The conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node... The conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node dissection... PurposeThe conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 390 |
| SubjectTerms | Amino acids Aorta Avidity Biopsy Bone marrow Cardiology Choline Computed tomography Diagnostic systems Flow charts Fluorine isotopes Histology Humans Imaging Invasiveness Lymph nodes Lymphatic Metastasis Lymphatic system Male Mathematical analysis Medicine Medicine & Public Health Metastases Neoplasm Staging Nomograms Nuclear Medicine Oncology Oncology – Genitourinary Original Article Orthopedics Parameters Patients Performance indices Positron Emission Tomography Computed Tomography Prospective Studies Prostate cancer Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Radiation therapy Radiology Risk Sensitivity Statistical analysis |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BixAXaIGWhYJ84AYWiZ2Hw62quuJCVbVbVAmhyE-p0iqp9sEf4I8z43WCUEulcspl7MTjSfxN5vEBvDelcGVp0S1p8sALWQeulUUg54QziMhF8EUkm6hPTtTlZXOaisKWQ7b7EJKMX-qx2I2O54ZTSkFGJEu8egjbeNwpImw4O_82xg7IhyA3C10DXqNFp1KZ2-f4-zi6gTFvxEfjsTN99n8PvANPE8xkhxu72IUHvnsOj7-mQPoL-PU9V9MffDpfWxSgvwqenR7PPh3NGKJYdr3w_bXfNAVnXe9wKkSRxGfErjpGLY455aSjXOxVgdc-ViYxS0a0-MwCkW0xdOXX89WS9YHpKJPKOlnkCnkJF9Pj2dEXnvgYuJWFWHEXCgoboj8dSqWqEFzmtZRCOlHUda7zmno1e5MFY20o8lBLLYQXKrgKgWgp92Cr6zv_CpjSwbisCoUqTWG01plHHGlKI6tG5EFNIB-2pbWpWTlxZszbsc1y1G6L2m2jdttqAh_GMWn5d0ofDLvdptd22QpyjxtVKjGB_Y0FjFOhCnKJ65jAx2G7_wz8931e30_8DTwRZDExYeYAtlaLtX8Lj-zP1dVy8S4a-m-rs_Zt priority: 102 providerName: Springer Nature |
| Title | [18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial |
| URI | https://link.springer.com/article/10.1007/s00259-021-05429-6 https://www.ncbi.nlm.nih.gov/pubmed/34213609 https://www.proquest.com/docview/2614498582 |
| Volume | 49 |
| WOSCitedRecordID | wos000669193800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1619-7089 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0018289 issn: 1619-7070 databaseCode: RSV dateStart: 20020101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xuwhx4f0oLJUP3MDaxHk5XBCsWnGhikpZVSAU-SmtVCWlD_4Af5wZ1-0KrdgLF-cytuPMxJ7xPD6A17oQtigMmiV16nmeVZ4raVCRs8Jq1MiFd3kAm6gmEzmf1028cFvHsMr9nhg2atsbuiM_E2S51LKQ4v3yJyfUKPKuRgiNIzihKgkihO41By8CWRNkcKGRwCuU7Zg0E1Ln6LCvOQUoJATZxMu_D6Zr2uY1T2k4gMb3__fVH8C9qHqyDztZeQi3XPcI7nyOzvXH8Pt7Ksc_-HixNUhANw2ONaPZ2fmMoWbLlivXL92uUDjreotDoWZJGEfssmNU9phTnDrShfoV-OxDthIzJFird8wTABdD83672KxZ75kKNDHVkwX8kCfwdTyanX_iEaOBmywXG259Tq5EtLF9IWXpvU2cyjKRWZFXVarSiuo3O514bYzPU19lSggnpLclKqdF9hSOu75zz4FJ5bVNSp_LQudaKZU41C11obOyFqmXA0j3DGpNLGBOOBqL9lB6OTC1Raa2galtOYA3hz5x-TdSn-4Z2MZfed1ecW8Az3aycBgKP0Ga4ToG8HYvHFcd_z3Pi5vneQl3BQlmCJo5hePNautewW3za3O5Xg3hqJpeUDuvhnDycTRppsMg9tg2xTdsp18u_gBUTQYw |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VBUEvvGkXCvgAJ7CaOE7iVEIIla5atV3tYZEqEAqJH1KlVbJNdkGc-T_8xs54k61QRW89cMrFD8X5xvnGnpkP4HUZCxPHGt2SLHRcRqnjhdJI5IwwJTJy4az0YhPpaKROT7PxGvzpc2EorLLfE_1GbWpNZ-Q7gjyXTMVKfJidc1KNotvVXkJjCYsj--snumzt-8NP-H3fCDHcn-wd8E5VgOtIijk3TtLlF3qFLlYqcc4EtogiERkh0zQswpQqDtsycKXWToYujQohrFDOJEinSCUCt_xbUoqArGgcf1ndWpD3Qg4eOiU8RVvqknR8qh6Ri4xTQERAElE8-ftHeIXdXrmZ9T-84f3_bakewL2OWrOPS1t4CGu2egR3Trrggcfw-2uoht_4cLrQ2IBOUiwb70929iYMmTubNbae2WUhdFbVBodC5kwaTuysYlTWmVMcPrbz9TnwWftsLKbJcJpd5khgjDW2XUznLasdK3ybLpWVeX2UJ_D5RpbgKaxXdWW3gKnClSZInFRxKcuiKAKL3LmMyyjJROjUAMIeELnuCrSTTsg0X5WW9iDKEUS5B1GeDODtqk_3-te23u4Bk3dbVZtfomUAm0vsrYbCJQgjfI8BvOvBeNnx3_M8u36eV3D3YHJynB8fjo6ew4Ygo_ABQtuwPm8W9gXc1j_mZ23z0psXg-83DdILXX5d7w |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VBVVceD-2FPABTmBt4rwcJIRQ24iqsNrDIlUgFBI_pEqrZJvsgjjzr_h1zHidrVBFbz1wysUPxfnG-caemQ_geZ0InSQK3ZI8tDyOMssrqZDIaaFrZOTCmtiJTWSTiTw5yadb8HvIhaGwymFPdBu1bhWdkY8FeS65TKQYWx8WMT0o3i7OOClI0U3rIKexhsix-fkD3bf-zdEBfusXQhSHs_333CsMcBXFYsm1jekiDD1Em0iZWqsDU0WRiLSIsyyswoyqD5s6sLVSNg5tFlVCGCGtTpFakWIEbv_XMvQxKZxwmnze3GCQJ0POHjooPEO78gk7Lm2PiEbOKTgiILkonv79U7zAdC_c0rqfX3Hrf16223DTU272bm0jd2DLNHdh56MPKrgHv76EsvjKi_lKYQM6YTFsejgb788YMnq26Ey7MOsC6axpNQ6FjJq0ndhpw6jcM6f4fGzn6nbgs3VZWkyRQXWvmSXhMdaZfjVf9qy1rHJtfIorc7op9-HTlSzBA9hu2sY8AiYrW-sgtbFM6riuqiowyKnrpI7SXIRWjiAcwFEqX7id9EPm5abktANUiYAqHaDKdAQvN33861_aem8AT-m3sL48R84IHq5xuBkKlyCM8D1G8GoA5nnHf8-ze_k8z2AHsVl-OJocP4YbguzDxQ3twfayW5kncF19X5723VNnaQy-XTVG_wAAJma5 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%5B18F%5D-Fluciclovine+PET%2FCT+for+preoperative+nodal+staging+in+high-risk+primary+prostate+cancer%3A+final+results+of+a+prospective+trial&rft.jtitle=European+journal+of+nuclear+medicine+and+molecular+imaging&rft.au=Zanoni%2C+Lucia&rft.au=Bianchi%2C+Lorenzo&rft.au=Nanni%2C+Cristina&rft.au=Pultrone+Cristian&rft.date=2021-12-01&rft.pub=Springer+Nature+B.V&rft.issn=1619-7070&rft.eissn=1619-7089&rft.volume=49&rft.issue=1&rft.spage=390&rft.epage=409&rft_id=info:doi/10.1007%2Fs00259-021-05429-6&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1619-7070&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1619-7070&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1619-7070&client=summon |